SINGLE CENTER, OPEN LABEL, RANDOMIZED TWO-WAY CROSSOVER STUDY OF THE EFFECT OF LACOSAMIDE 200MG TWICE DAILY ON THE SINGLE-DOSE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN (25 MG) IN HEALTHY MALE VOLUNTEERS

Published: 06-01-2012
Last updated: 01-05-2024

Primary objective:The primary objective of this study is to evaluate the effect of LCM 200mg bid on the single dose PK and PD of a single warfarin 25mg dose.Secondary objective:The secondary objective of this study is to monitor the safety and...

Ethical review	Approved WMO
Status	Recruitment stopped
Health condition type	Seizures (incl subtypes)
Study type	Interventional

Summary

ID

NL-OMON37817

Source
ToetsingOnline

Brief title
Lacosamide/Warfarin DDI study.

Condition

- Seizures (incl subtypes)

Synonym
Epilepsy, seizures (attacks)

Research involving
Human

Sponsors and support

Primary sponsor: UCB Pharma
Source(s) of monetary or material Support: Pharmaceutische industrie.

Intervention

Keyword: DDI, Epilepsy, Lacosamide

Outcome measures

Primary outcome

PK, PD, Safety and tolerability.

Secondary outcome

n/a.

Study description

Background summary

LCM is an investigational compound that is used for the treatment of epilepsy. In 2008 LCM was registered as adjunctive therapy in the treatment of partial onset seizures (epileptic attacks from one part of the brain) with or without secondary generalization (the epileptic attack begins in one part of the brain and expands to the whole brain) in patients with epilepsy, aged 16 years and older.

The purpose of the study is to investigate the interaction between LCM and Warfarin (this is called pharmacodynamics). In addition, it will be investigated how quickly and to what extent LCM is absorbed and eliminated from the body (this is called pharmacokinetics).
This study is not intended to improve your health, but is necessary for the further development of LCM in Elderly people. Warfarin is frequently administered in elderly people who may be at risk of epileptic attacks. Therefore, prior to initiating a clinical study in elderly patients with epilepsy, it is deemed important to rule out the possibility that the interaction between LCM and Warfarin might result in negative changes in the so

called PK and PD effects of Warfarin (often used in elderly).

Study objective

Primary objective:
The primary objective of this study is to evaluate the effect of LCM 200mg bid on the single dose PK and PD of a single warfarin 25mg dose.

Secondary objective:
The secondary objective of this study is to monitor the safety and tolerability of LCM 200mg bid, before and following concomitant administration of a single warfarin 25mg dose.

Study design

SINGLE CENTER, OPEN LABEL, RANDOMIZED TWO-WAY CROSSOVER STUDY OF THE EFFECT OF
LACOSAMIDE 200MG TWICE DAILY ON THE SINGLE-DOSE PHARMACOKINETICS AND PHARMACODYNAMICS OF WARFARIN (25 MG) IN HEALTHY MALE VOLUNTEERS.

The total treatment period will be up to 31 days with treatment A being 1 day and Treatment B being 1 * 9 days. The 2 treatments will be separated by a wash-out period of at least two weeks form the last blood sample of the first treatment period to the first dose of the second treatment period.

Treatment A will consist of a single 25mg oral dose of Warfarin (5 tablets).
Treatment B will consist of multiple oral dose administrations of LCM 200mg (1 tablet) twice daily (bid) and a single 25mg oral dose of Warfarin (5 tablets) on the third day of LCM treatment.

Further the study will consist of 2 period(s) during which you will stay in the clinical research centre in Zuidlaren.
Group 1 will stay in the clinic for Period 1 for 5 days (4 nights) and in Period 2 for 7 days (6 nights).
Group 2 will stay in the clinic for Period 1 for 7 days (6 nights) and in Period 2 for 5 days (4 nights).
For all groups, each period will be followed by 4 days during which you will visit the clinical research centre in Zuidlaren. The time interval between the 2 periods is at least 2 weeks.

Procedures:
Registration af adverse effects: During the entire investigation all adverse effects you report will be documented.

Blood draw, indwelling canula: During this study approximately 330 ml of blood will be drawn. It is anticipated that 2 time(s) an indwelling canula will be

used and 52 blood draws will be drawn by direct puncture of the vein..

Collection of urine and feces: Urine samples for safety laboratory tests will be taken in the morning at predose, ie, before the first administration of Warfarin (Treatment A) or LCM (Treatment B). Feces will be collected only at screening visit.

Heart trace (ECG*s): Group 1: ECG*s will be made regularly (also pre-dose): specifically on Days 1 and 2 (period 1) and Days 24 and 25 (Period 2). Group 2: ECG*s will be made regularly (also pre-dose): specifically on Days 3 and 4 (Period 1) and Days 24 and 25 (Period 2).

Vital signs: Vital signs will be assessed pre-dose and 4 and 12h after first administration of LCM in each Treatment Period.
Vital signs will be assessed pre-dose and 4, 12, and 24h after the Warfarin single dose in each Treatment Period.

Columbia Suicide Severity Rating Scale (C-SSRS): During the screening, stay at the research clinic and follow-up subjects will be asked to fill out the questionnaire of the Columbia Suicide Severity Rating Scale. This scale records the possibility, severity and frequency of suicide-related thoughts and behaviors during the study period. The questions asked may be confronting. This test is a safety measure.

Genotyping (bloodsampling): bloodsampling will be done only post-dose on Day 1.

Meals: Standard meals will be provided during confinement at the clinical center.

Intervention

n/a.

Study burden and risks

Procedures: pain, light bleeding, heamatoma, possibly an infection.

With the doses used in this study no serious adverse effects are expected. The occurrence of known or other effects cannot be excluded. All potential drugs cause adverse events to some extent. See SmPC of Lacosamide and Warfarin.

Contacts

Public

UCB Pharma

Allée de la Recherche 60
B-1070 Brussels
BE
Scientific
UCB Pharma

Allée de la Recherche 60
B-1070 Brussels
BE

Trial sites

Listed location countries

Netherlands

Eligibility criteria

Age
Adults (18-64 years)
Elderly (65 years and older)

Inclusion criteria

Healthy Male between18-55 yrs,,
18.0-30.0 kg/m2, with a body weight of at least 50 kg.
Non-smoking

Exclusion criteria

Suffering from: hepatitis B, C, cancer or HIV/AIDS. In case of participation in another drug study within 60 days before the start of this study or being a blood donor within 60 days from the start of the study or in case of donating more than 1.5 liter of blood in the 10 months prior the start of this study.

Study design

Design

Study type:	Interventional
Intervention model:	Crossover
Masking:	Open (masking not used)
Control:	Uncontrolled
Primary purpose:	Treatment

Recruitment

NL

Recruitment status:	Recruitment stopped
Start date (anticipated):	16-01-2012
Enrollment:	16
Type:	Actual

Medical products/devices used

Product type:	Medicine
Brand name:	Coumadin®
Generic name:	Warfarin
Product type:	Medicine
Brand name:	Vimpat®
Generic name:	Lacosamide
Registration:	Yes - NL intended use

Ethics review

Approved WMO Date:	06-01-2012
Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)
Approved WMO Date:	13-01-2012

Application type:	First submission
Review commission:	BEBO: Stichting Beoordeling Ethiek Bio-Medisch Onderzoek (Assen)

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
EudraCT	EUCTR2011-004911-21-NL
CCMO	NL38884.056.11